Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: Comparison with imipenem/cilastatin
Abstract Background Treatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin (TAZ/PIPC) in aspiration pneumonia is not clear. Purpose To compare clinical efficacy between TAZ/PIPC (1:4 compound) and imipenem/cila...
Saved in:
| Published in | Pulmonary pharmacology & therapeutics Vol. 23; no. 5; pp. 403 - 410 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.10.2010
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Background Treatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin (TAZ/PIPC) in aspiration pneumonia is not clear. Purpose To compare clinical efficacy between TAZ/PIPC (1:4 compound) and imipenem/cilastatin (IPM/CS) in patients with moderate-to-severe aspiration pneumonia. Patients and methods In this open-label, randomized study either TAZ/PIPC 5 g or IPM/CS 1 g was intravenously administered every 12 h to patients with moderate-to-severe community-acquired aspiration pneumonia or nursing home-acquired pneumonia with risk for aspiration pneumonia for average 11 days. The primary outcome was clinical response rate at the end of treatment (EOT) in validated per-protocol (VPP) population. Secondary outcomes were clinical response during treatment (days 4 and 7) and at the end of study (EOS) in VPP population, and survival at day 30 in modified intention-to-treat (MITT) population. Results There was no difference between the groups in primary or secondary outcome. However, significantly faster improvement as measured by axillary temperature ( p < 0.05) and WBC count ( p = 0.01) was observed under TAZ/PIPC treatment. In patients with gram-positive bacterial infection, TAZ/PIPC was more effective at EOT in VPP population ( p = 0.03). Conclusion TAZ/PIPC is as effective and safe as IPM/CS in the treatment of moderate- to-severe aspiration pneumonia. |
|---|---|
| AbstractList | Treatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin (TAZ/PIPC) in aspiration pneumonia is not clear.
To compare clinical efficacy between TAZ/PIPC (1:4 compound) and imipenem/cilastatin (IPM/CS) in patients with moderate-to-severe aspiration pneumonia.
In this open-label, randomized study either TAZ/PIPC 5 g or IPM/CS 1 g was intravenously administered every 12 h to patients with moderate-to-severe community-acquired aspiration pneumonia or nursing home-acquired pneumonia with risk for aspiration pneumonia for average 11 days. The primary outcome was clinical response rate at the end of treatment (EOT) in validated per-protocol (VPP) population. Secondary outcomes were clinical response during treatment (days 4 and 7) and at the end of study (EOS) in VPP population, and survival at day 30 in modified intention-to-treat (MITT) population.
There was no difference between the groups in primary or secondary outcome. However, significantly faster improvement as measured by axillary temperature (
p < 0.05) and WBC count (
p = 0.01) was observed under TAZ/PIPC treatment. In patients with gram-positive bacterial infection, TAZ/PIPC was more effective at EOT in VPP population (
p = 0.03).
TAZ/PIPC is as effective and safe as IPM/CS in the treatment of moderate- to-severe aspiration pneumonia. Abstract Background Treatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin (TAZ/PIPC) in aspiration pneumonia is not clear. Purpose To compare clinical efficacy between TAZ/PIPC (1:4 compound) and imipenem/cilastatin (IPM/CS) in patients with moderate-to-severe aspiration pneumonia. Patients and methods In this open-label, randomized study either TAZ/PIPC 5 g or IPM/CS 1 g was intravenously administered every 12 h to patients with moderate-to-severe community-acquired aspiration pneumonia or nursing home-acquired pneumonia with risk for aspiration pneumonia for average 11 days. The primary outcome was clinical response rate at the end of treatment (EOT) in validated per-protocol (VPP) population. Secondary outcomes were clinical response during treatment (days 4 and 7) and at the end of study (EOS) in VPP population, and survival at day 30 in modified intention-to-treat (MITT) population. Results There was no difference between the groups in primary or secondary outcome. However, significantly faster improvement as measured by axillary temperature ( p < 0.05) and WBC count ( p = 0.01) was observed under TAZ/PIPC treatment. In patients with gram-positive bacterial infection, TAZ/PIPC was more effective at EOT in VPP population ( p = 0.03). Conclusion TAZ/PIPC is as effective and safe as IPM/CS in the treatment of moderate- to-severe aspiration pneumonia. BACKGROUNDTreatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin (TAZ/PIPC) in aspiration pneumonia is not clear.PURPOSETo compare clinical efficacy between TAZ/PIPC (1:4 compound) and imipenem/cilastatin (IPM/CS) in patients with moderate-to-severe aspiration pneumonia.PATIENTS AND METHODSIn this open-label, randomized study either TAZ/PIPC 5 g or IPM/CS 1 g was intravenously administered every 12 h to patients with moderate-to-severe community-acquired aspiration pneumonia or nursing home-acquired pneumonia with risk for aspiration pneumonia for average 11 days. The primary outcome was clinical response rate at the end of treatment (EOT) in validated per-protocol (VPP) population. Secondary outcomes were clinical response during treatment (days 4 and 7) and at the end of study (EOS) in VPP population, and survival at day 30 in modified intention-to-treat (MITT) population.RESULTSThere was no difference between the groups in primary or secondary outcome. However, significantly faster improvement as measured by axillary temperature (p < 0.05) and WBC count (p = 0.01) was observed under TAZ/PIPC treatment. In patients with gram-positive bacterial infection, TAZ/PIPC was more effective at EOT in VPP population (p = 0.03).CONCLUSIONTAZ/PIPC is as effective and safe as IPM/CS in the treatment of moderate- to-severe aspiration pneumonia. Treatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin (TAZ/PIPC) in aspiration pneumonia is not clear. To compare clinical efficacy between TAZ/PIPC (1:4 compound) and imipenem/cilastatin (IPM/CS) in patients with moderate-to-severe aspiration pneumonia. In this open-label, randomized study either TAZ/PIPC 5 g or IPM/CS 1 g was intravenously administered every 12 h to patients with moderate-to-severe community-acquired aspiration pneumonia or nursing home-acquired pneumonia with risk for aspiration pneumonia for average 11 days. The primary outcome was clinical response rate at the end of treatment (EOT) in validated per-protocol (VPP) population. Secondary outcomes were clinical response during treatment (days 4 and 7) and at the end of study (EOS) in VPP population, and survival at day 30 in modified intention-to-treat (MITT) population. There was no difference between the groups in primary or secondary outcome. However, significantly faster improvement as measured by axillary temperature (p < 0.05) and WBC count (p = 0.01) was observed under TAZ/PIPC treatment. In patients with gram-positive bacterial infection, TAZ/PIPC was more effective at EOT in VPP population (p = 0.03). TAZ/PIPC is as effective and safe as IPM/CS in the treatment of moderate- to-severe aspiration pneumonia. |
| Author | Yasutomo, Yoshiro Kadowaki, Seizo Matsumoto, Hisako Nakai, Asako Ito, Isao Kase, Masahito Niimi, Akio Ichiyama, Satoshi Haruna, Akane Tanabe, Naoya Tsukino, Mitsuhiro Mishima, Michiaki Chin, Kazuo |
| Author_xml | – sequence: 1 fullname: Ito, Isao – sequence: 2 fullname: Kadowaki, Seizo – sequence: 3 fullname: Tanabe, Naoya – sequence: 4 fullname: Haruna, Akane – sequence: 5 fullname: Kase, Masahito – sequence: 6 fullname: Yasutomo, Yoshiro – sequence: 7 fullname: Tsukino, Mitsuhiro – sequence: 8 fullname: Nakai, Asako – sequence: 9 fullname: Matsumoto, Hisako – sequence: 10 fullname: Niimi, Akio – sequence: 11 fullname: Chin, Kazuo – sequence: 12 fullname: Ichiyama, Satoshi – sequence: 13 fullname: Mishima, Michiaki |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20561917$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtv1TAQhS1URB_wB1ig7Fjl1nYcJ0YIqbriJVViQVlbjjMRvk1sYztFZckvZ8ItLFiwsjXznRnNOefkxAcPhDxndMcok5eHXVxj2XGKBdruKO0ekTPWcl4rydUJ_qkSdds26pSc53ygSIimfUJOOW0lU6w7Iz9vzI8wGFvMchldhGSsm2fnqymkagkjFgrUJdQZ7iBBFT2sS_DOVMhEUxz4kqvvrnytksu3v2UmR4cyF_yrah-WaLAT_BFyCy7xsFziGpMLUv4peTyZOcOzh_eCfHn39mb_ob7-9P7j_uq6tkL1pR4aYaa-g56KwRg1MRhFxybedkzIqZec94OSkonGWNrjoYPpJ9Ur3nRyFIo2F-TlcW5M4dsKuejFZQvzbDyENetO9Ep2UjEk-ZG0KeScYNIxucWke82o3qzXB71ZrzfrNW01GouiFw_j12GB8a_kj9cIvD4CgEfeOUg6W7TPwugS2KLH4P4__80_cos5OWvmW7iHfAhr8mifZjpzTfXnLfwte0a33LlsfgEz_66A |
| CitedBy_id | crossref_primary_10_1111_aas_14239 crossref_primary_10_1016_j_resinv_2015_01_003 crossref_primary_10_1093_jac_dku351 crossref_primary_10_1248_bpb_b14_00362 crossref_primary_10_1111_jgs_13250 crossref_primary_10_1542_peds_2015_1612 crossref_primary_10_1080_20018525_2024_2335721 crossref_primary_10_1016_j_jiac_2015_12_019 crossref_primary_10_1016_j_resinv_2012_11_001 crossref_primary_10_1186_s12890_020_01198_4 crossref_primary_10_1016_j_ijantimicag_2016_03_008 crossref_primary_10_1016_j_jiac_2019_08_005 crossref_primary_10_11150_kansenshogakuzasshi_88_1 crossref_primary_10_1007_s10156_013_0605_x crossref_primary_10_1016_j_jiac_2021_04_022 crossref_primary_10_1016_j_jiac_2020_06_012 crossref_primary_10_1371_journal_pone_0274685 crossref_primary_10_37489_2782_3784_myrwd_36 crossref_primary_10_1136_thorax_2022_219699 crossref_primary_10_1038_s41598_021_03440_3 crossref_primary_10_1186_s13054_021_03762_8 crossref_primary_10_1016_j_jiac_2015_05_001 crossref_primary_10_2146_ajhp120319 crossref_primary_10_1007_s10096_013_2034_2 |
| Cites_doi | 10.1086/511159 10.1128/AAC.46.1.220-224.2002 10.1016/j.rmed.2008.03.027 10.1128/AAC.42.11.2966 10.1086/428574 10.1111/j.1469-0691.2004.00774.x 10.1016/j.ejrad.2008.08.004 10.1016/S0924-8579(00)00277-6 10.1128/AAC.41.11.2511 10.1164/ajrccm.150.1.8025758 10.1128/AAC.46.9.2920-2925.2002 10.1056/NEJM199701233360402 10.1128/AAC.39.2.445 10.1164/rccm.200405-644ST 10.1086/516294 10.1093/jac/43.3.389 10.2169/internalmedicine.48.1308 10.1016/j.clinthera.2008.12.009 10.1056/NEJM200103013440908 10.1378/chest.108.4.937 10.1093/jac/dki348 10.1164/rccm.200212-1543OC 10.1128/AAC.43.6.1379 10.1016/0002-9343(74)90598-1 10.1592/phco.22.8.569.33209 10.18356/fe74b223-en 10.1378/chest.08-1357 10.1086/431588 10.1378/chest.127.4.1276 10.1128/AAC.00851-07 10.1007/s15010-007-7043-6 10.2169/internalmedicine.45.1717 10.1378/chest.128.6.3854 10.1007/s15010-006-5020-0 10.1016/j.rmed.2006.01.004 |
| ContentType | Journal Article |
| Copyright | Elsevier Ltd 2010 Elsevier Ltd Copyright 2010 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: Elsevier Ltd – notice: 2010 Elsevier Ltd – notice: Copyright 2010 Elsevier Ltd. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.pupt.2010.05.007 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1522-9629 |
| EndPage | 410 |
| ExternalDocumentID | 10_1016_j_pupt_2010_05_007 20561917 S1094553910000726 1_s2_0_S1094553910000726 |
| Genre | Randomized Controlled Trial Journal Article Comparative Study |
| GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXUO ABBQC ABFRF ABJNI ABMAC ABMZM ABXDB ABZDS ACDAQ ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OGGZJ OI- OU. OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SSH SSP SSZ T5K UHS UNMZH XPP Z5R ZMT ZU3 ~G- AAIAV AATCM ABLVK ABYKQ AJBFU EFLBG LCYCR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c498t-b34af87e804baa9f1ed471f257146f86228b966143ac08743ba8f9892376d4903 |
| IEDL.DBID | .~1 |
| ISSN | 1094-5539 |
| IngestDate | Fri Oct 25 04:07:26 EDT 2024 Thu Sep 26 19:35:25 EDT 2024 Sat Sep 28 07:47:44 EDT 2024 Fri Feb 23 02:34:24 EST 2024 Tue Oct 15 22:55:56 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Nursing home-acquired pneumonia (NHAP) Tazobactam/piperacillin (TAZ/PIPC) Community-acquired pneumonia (CAP) Open-label randomized study Aspiration Imipenem/cilastain (IPM/CS) |
| Language | English |
| License | Copyright 2010 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c498t-b34af87e804baa9f1ed471f257146f86228b966143ac08743ba8f9892376d4903 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | http://hdl.handle.net/2433/126728 |
| PMID | 20561917 |
| PQID | 748967691 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_748967691 crossref_primary_10_1016_j_pupt_2010_05_007 pubmed_primary_20561917 elsevier_sciencedirect_doi_10_1016_j_pupt_2010_05_007 elsevier_clinicalkeyesjournals_1_s2_0_S1094553910000726 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-10-01 |
| PublicationDateYYYYMMDD | 2010-10-01 |
| PublicationDate_xml | – month: 10 year: 2010 text: 2010-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Pulmonary pharmacology & therapeutics |
| PublicationTitleAlternate | Pulm Pharmacol Ther |
| PublicationYear | 2010 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Carmeli, Troillet, Eliopoulos, Samore (bib14) 1999; 43 Maruyama, Niederman, Kobayashi, Kobayashi, Takagi, D’Alessandro-Gabazza (bib26) 2008; 102 El-Solh, Pietrantoni, Bhat, Aquilina, Okada, Grover (bib8) 2003; 167 Micek, Kollef, Reichley, Roubinian, Kollef (bib28) 2007; 51 Marik (bib21) 2001; 344 United Nations Population Division (bib1) 2007 Jaccard, Troillet, Harbarth, Zanetti, Aymon, Schneider (bib31) 1998; 42 Sanguinetti, De Benedettob, Miragliotta (bib9) 2000; 16 Yanagihara, Fukuda, Seki, Izumikawa, Higashiyama, Miyazaki (bib13) 2006; 45 Fine, Auble, Yealy, Hanusa, Weissfeld, Singer (bib17) 1997; 336 Mikamo, Yamagishi (bib37) 2008; 32 Templeton, Scheltinga, van den Eeden, Graffelman, van den Broek, Claas (bib10) 2005; 41 World Health Organization (bib2) 2004 Lepper, Grusa, Reichl, Högel, Trautmann (bib15) 2002; 46 Kadowaki, Demura, Mizuno, Uesaka, Ameshima, Miyamori (bib11) 2005; 127 American Thoracic Society; Infectious Diseases Society of America (bib30) 2005; 171 Brun-Buisson, Sollet, Schweich, Brière, Petit (bib35) 1998; 26 Shindo, Sato, Maruyama, Ohashi, Ogawa, Hashimoto (bib27) 2009; 135 Higashiya, Mihashi (bib41) 1994; 42 Frei, Burgess (bib40) 2008; 30 Allewelt, Schüler, Bölcskei, Mauch, Lode (bib20) 2004; 10 Kim, Capitano, Mattoes, Xuan, Quintiliani, Nightingale (bib38) 2002; 5 Ministry of Health Labour and Welfare, Government of Japan (bib3) 2007 Kollef, Shorr, Tabak, Gupta, Liu, Johannes (bib29) 2005; 128 Joshi, Metzler, McCarthy, Olvey, Kassira, Cooper (bib32) 2006; 100 Hammond, Potgieter, Hanslo, Scott, Roditi (bib5) 1995; 108 Joshi, Bernstein, Solomkin, Wester, Kuye (bib34) 1999; 43 Bartlett, Gorbach, Finegold (bib7) 1974; 56 Cometta, Zinner, de Bock, Calandra, Gaya, Klastersky (bib25) 1995; 39 Edmiston, Krepel, Kehl, Seabrook, Somberg, Almassi (bib24) 2005; 56 Occhipinti, Pendland, Schoonover, Rypins, Danziger, Rodvold (bib39) 1997; 41 Wang, Chen, Fang, Hsueh, Yang, Chang (bib6) 2005; 40 British Thoracic Society Pneumonia Guidelines Committee. BTS guidelines for the management of community acquired pneumonia in adults–2004 update. Kikuchi, Watabe, Konno, Mishina, Sekizawa, Sasaki (bib4) 1994; 150 Ott, Allewelt, Lorenz, Reimnitz, Lode (bib19) 2008; 36 Hoellman, Kelly, Credito, Anthony, Ednie, Jacobs (bib23) 2002; 46 Tokuyasu, Harada, Watanabe, Okazaki, Touge, Kawasaki (bib12) 2009; 48 Mandell, Wunderink, Anzueto, Bartlett, Campbell, Dean (bib16) 2007; 44 Matsumoto, Nagatake, Oishi, Amamoto, Urae, Niki (bib36) 1994; 42 Ito, Ishida, Togashi, Niimi, Koyama, Ishimori (bib22) 2009; 72 Schmitt, Leitner, Welte, Lode (bib33) 2006; 34 Yanagihara (10.1016/j.pupt.2010.05.007_bib13) 2006; 45 Frei (10.1016/j.pupt.2010.05.007_bib40) 2008; 30 Carmeli (10.1016/j.pupt.2010.05.007_bib14) 1999; 43 Cometta (10.1016/j.pupt.2010.05.007_bib25) 1995; 39 Kadowaki (10.1016/j.pupt.2010.05.007_bib11) 2005; 127 Mandell (10.1016/j.pupt.2010.05.007_bib16) 2007; 44 Ito (10.1016/j.pupt.2010.05.007_bib22) 2009; 72 Ministry of Health Labour and Welfare, Government of Japan (10.1016/j.pupt.2010.05.007_bib3) 2007 Edmiston (10.1016/j.pupt.2010.05.007_bib24) 2005; 56 Bartlett (10.1016/j.pupt.2010.05.007_bib7) 1974; 56 Brun-Buisson (10.1016/j.pupt.2010.05.007_bib35) 1998; 26 10.1016/j.pupt.2010.05.007_bib18 Maruyama (10.1016/j.pupt.2010.05.007_bib26) 2008; 102 Kollef (10.1016/j.pupt.2010.05.007_bib29) 2005; 128 Joshi (10.1016/j.pupt.2010.05.007_bib34) 1999; 43 Hammond (10.1016/j.pupt.2010.05.007_bib5) 1995; 108 Shindo (10.1016/j.pupt.2010.05.007_bib27) 2009; 135 Kim (10.1016/j.pupt.2010.05.007_bib38) 2002; 5 Higashiya (10.1016/j.pupt.2010.05.007_bib41) 1994; 42 Wang (10.1016/j.pupt.2010.05.007_bib6) 2005; 40 Matsumoto (10.1016/j.pupt.2010.05.007_bib36) 1994; 42 World Health Organization (10.1016/j.pupt.2010.05.007_bib2) 2004 Micek (10.1016/j.pupt.2010.05.007_bib28) 2007; 51 Tokuyasu (10.1016/j.pupt.2010.05.007_bib12) 2009; 48 Fine (10.1016/j.pupt.2010.05.007_bib17) 1997; 336 Allewelt (10.1016/j.pupt.2010.05.007_bib20) 2004; 10 Lepper (10.1016/j.pupt.2010.05.007_bib15) 2002; 46 Mikamo (10.1016/j.pupt.2010.05.007_bib37) 2008; 32 Kikuchi (10.1016/j.pupt.2010.05.007_bib4) 1994; 150 Templeton (10.1016/j.pupt.2010.05.007_bib10) 2005; 41 Joshi (10.1016/j.pupt.2010.05.007_bib32) 2006; 100 Occhipinti (10.1016/j.pupt.2010.05.007_bib39) 1997; 41 Schmitt (10.1016/j.pupt.2010.05.007_bib33) 2006; 34 Jaccard (10.1016/j.pupt.2010.05.007_bib31) 1998; 42 Hoellman (10.1016/j.pupt.2010.05.007_bib23) 2002; 46 Ott (10.1016/j.pupt.2010.05.007_bib19) 2008; 36 Marik (10.1016/j.pupt.2010.05.007_bib21) 2001; 344 American Thoracic Society; Infectious Diseases Society of America (10.1016/j.pupt.2010.05.007_bib30) 2005; 171 United Nations Population Division (10.1016/j.pupt.2010.05.007_bib1) 2007 El-Solh (10.1016/j.pupt.2010.05.007_bib8) 2003; 167 Sanguinetti (10.1016/j.pupt.2010.05.007_bib9) 2000; 16 |
| References_xml | – volume: 150 start-page: 251 year: 1994 end-page: 253 ident: bib4 article-title: High incidence of silent aspiration in elderly patients with community-acquired pneumonia publication-title: Am J Respir Crit Care Med contributor: fullname: Sasaki – volume: 108 start-page: 937 year: 1995 end-page: 941 ident: bib5 article-title: The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess publication-title: Chest contributor: fullname: Roditi – volume: 40 start-page: 915 year: 2005 end-page: 922 ident: bib6 article-title: Changing bacteriology of adult community-acquired lung abscess in Taiwan: publication-title: Clin Infect Dis contributor: fullname: Chang – volume: 42 start-page: 2966 year: 1998 end-page: 2972 ident: bib31 article-title: Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis publication-title: Antimicrob Agents Chemother contributor: fullname: Schneider – year: 2007 ident: bib1 article-title: World population prospects: the 2006 revision contributor: fullname: United Nations Population Division – volume: 39 start-page: 445 year: 1995 end-page: 452 ident: bib25 article-title: Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer publication-title: Antimicrob Agents Chemother contributor: fullname: Klastersky – volume: 46 start-page: 2920 year: 2002 end-page: 2925 ident: bib15 article-title: Consumption of imipenem correlates with ß-lactam resistance in publication-title: Antimicrob Agents Chemother contributor: fullname: Trautmann – volume: 100 start-page: 1554 year: 2006 end-page: 1565 ident: bib32 article-title: Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia publication-title: Respir Med contributor: fullname: Cooper – volume: 167 start-page: 1650 year: 2003 end-page: 1654 ident: bib8 article-title: Microbiology of severe aspiration pneumonia in institutionalized elderly publication-title: Am J Respir Crit Care Med contributor: fullname: Grover – volume: 42 start-page: 281 year: 1994 end-page: 299 ident: bib36 article-title: Evaluation of emergence of beta-lactam resistance in publication-title: Chemotherapy contributor: fullname: Niki – volume: 102 start-page: 1287 year: 2008 end-page: 1295 ident: bib26 article-title: A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly publication-title: Respir Med contributor: fullname: D’Alessandro-Gabazza – volume: 41 start-page: 2511 year: 1997 end-page: 2517 ident: bib39 article-title: Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens publication-title: Antimicrob Agents Chemother contributor: fullname: Rodvold – volume: 41 start-page: 345 year: 2005 end-page: 351 ident: bib10 article-title: Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction publication-title: Clin Infect Dis contributor: fullname: Claas – volume: 56 start-page: 202 year: 1974 end-page: 207 ident: bib7 article-title: The bacteriology of aspiration pneumonia publication-title: Am J Med contributor: fullname: Finegold – volume: 36 start-page: 23 year: 2008 end-page: 30 ident: bib19 article-title: German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess publication-title: Infection contributor: fullname: Lode – volume: 44 start-page: S27 year: 2007 end-page: S72 ident: bib16 article-title: Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults publication-title: Clin Infect Dis contributor: fullname: Dean – volume: 5 start-page: 569 year: 2002 end-page: 577 ident: bib38 article-title: Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam publication-title: Pharmacotherapy contributor: fullname: Nightingale – volume: 45 start-page: 995 year: 2006 end-page: 999 ident: bib13 article-title: Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia publication-title: Intern Med contributor: fullname: Miyazaki – volume: 344 start-page: 665 year: 2001 end-page: 671 ident: bib21 article-title: Aspiration pneumonitis and aspiration pneumonia publication-title: N Engl J Med contributor: fullname: Marik – volume: 336 start-page: 243 year: 1997 end-page: 250 ident: bib17 article-title: A prediction rule to identify low-risk patients with community-acquired pneumonia publication-title: N Engl J Med contributor: fullname: Singer – volume: 56 start-page: 872 year: 2005 end-page: 878 ident: bib24 article-title: Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients publication-title: J Antimicrob Chemother contributor: fullname: Almassi – volume: 30 start-page: 2335 year: 2008 end-page: 2341 ident: bib40 article-title: Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002 publication-title: Clin Ther contributor: fullname: Burgess – volume: 26 start-page: 346 year: 1998 end-page: 354 ident: bib35 article-title: Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial publication-title: Clin Infect Dis contributor: fullname: Petit – volume: 127 start-page: 1276 year: 2005 end-page: 1282 ident: bib11 article-title: Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients publication-title: Chest contributor: fullname: Miyamori – volume: 51 start-page: 3568 year: 2007 end-page: 3573 ident: bib28 article-title: Health care-associated pneumonia and community-acquired pneumonia: a single-center experience publication-title: Antimicrob Agents Chemother contributor: fullname: Kollef – volume: 72 start-page: 388 year: 2009 end-page: 395 ident: bib22 article-title: Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography publication-title: Eur J Radiol contributor: fullname: Ishimori – volume: 171 start-page: 388 year: 2005 end-page: 416 ident: bib30 article-title: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia publication-title: Am J Respir Crit Care Med contributor: fullname: American Thoracic Society; Infectious Diseases Society of America – volume: 43 start-page: 389 year: 1999 end-page: 397 ident: bib34 article-title: Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection publication-title: J Antimicrob Chemother contributor: fullname: Kuye – volume: 128 start-page: 3854 year: 2005 end-page: 3862 ident: bib29 article-title: Epidemiology and outcomes of health-care-associated pneumonia. Results from a large US database of culture-positive pneumonia publication-title: Chest contributor: fullname: Johannes – volume: 135 start-page: 633 year: 2009 end-page: 640 ident: bib27 article-title: Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital publication-title: Chest contributor: fullname: Hashimoto – volume: 32 start-page: 269 year: 2008 end-page: 279 ident: bib37 article-title: Strategic use of antimicrobial agents based on pharmacokinetics-pharmacodynamics (PK-PD) theory (in Japanese) publication-title: ICC & CCU contributor: fullname: Yamagishi – volume: 42 start-page: 26 year: 1994 end-page: 33 ident: bib41 article-title: Evaluation of antimicrobial effects and optimal ratio of tazobactam/piperacillin combination (in Japanese) publication-title: Chemotherapy contributor: fullname: Mihashi – volume: 46 start-page: 220 year: 2002 end-page: 224 ident: bib23 article-title: In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds publication-title: Antimicrob Agents Chemother contributor: fullname: Jacobs – volume: 48 start-page: 129 year: 2009 end-page: 135 ident: bib12 article-title: Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients publication-title: Intern Med contributor: fullname: Kawasaki – volume: 43 start-page: 1379 year: 1999 end-page: 1382 ident: bib14 article-title: Emergence of antibiotic-resistant publication-title: Antimicrob Agents Chemother contributor: fullname: Samore – volume: 10 start-page: 163 year: 2004 end-page: 170 ident: bib20 article-title: Study Group on Aspiration Pneumonia. Ampicillin + sulbactam vs. clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess publication-title: Clin Microbiol Infect contributor: fullname: Lode – volume: 34 start-page: 127 year: 2006 end-page: 134 ident: bib33 article-title: Piperacillin/tazobactam vs imipenem/vilastatin in the treatment of nosocomial pneumonia—a double blind prospective multicentre study publication-title: Infection contributor: fullname: Lode – volume: 16 start-page: 467 year: 2000 end-page: 471 ident: bib9 article-title: DEDALO Study Group. Bacterial agents of lower respiratory tract infections (LRTIs), β-lactamase production, and resistance to antibiotics in elderly people publication-title: Int J Antimicrob Agents contributor: fullname: Miragliotta – year: 2007 ident: bib3 article-title: Summary of vital statistics 2006 (in Japanese) contributor: fullname: Ministry of Health Labour and Welfare, Government of Japan – year: 2004 ident: bib2 article-title: The World health report 2004 contributor: fullname: World Health Organization – volume: 44 start-page: S27 year: 2007 ident: 10.1016/j.pupt.2010.05.007_bib16 article-title: Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults publication-title: Clin Infect Dis doi: 10.1086/511159 contributor: fullname: Mandell – volume: 46 start-page: 220 year: 2002 ident: 10.1016/j.pupt.2010.05.007_bib23 article-title: In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.46.1.220-224.2002 contributor: fullname: Hoellman – volume: 102 start-page: 1287 year: 2008 ident: 10.1016/j.pupt.2010.05.007_bib26 article-title: A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly publication-title: Respir Med doi: 10.1016/j.rmed.2008.03.027 contributor: fullname: Maruyama – volume: 42 start-page: 2966 year: 1998 ident: 10.1016/j.pupt.2010.05.007_bib31 article-title: Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.42.11.2966 contributor: fullname: Jaccard – volume: 40 start-page: 915 year: 2005 ident: 10.1016/j.pupt.2010.05.007_bib6 article-title: Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes publication-title: Clin Infect Dis doi: 10.1086/428574 contributor: fullname: Wang – volume: 10 start-page: 163 year: 2004 ident: 10.1016/j.pupt.2010.05.007_bib20 article-title: Study Group on Aspiration Pneumonia. Ampicillin + sulbactam vs. clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2004.00774.x contributor: fullname: Allewelt – volume: 72 start-page: 388 year: 2009 ident: 10.1016/j.pupt.2010.05.007_bib22 article-title: Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2008.08.004 contributor: fullname: Ito – volume: 16 start-page: 467 year: 2000 ident: 10.1016/j.pupt.2010.05.007_bib9 article-title: DEDALO Study Group. Bacterial agents of lower respiratory tract infections (LRTIs), β-lactamase production, and resistance to antibiotics in elderly people publication-title: Int J Antimicrob Agents doi: 10.1016/S0924-8579(00)00277-6 contributor: fullname: Sanguinetti – volume: 41 start-page: 2511 year: 1997 ident: 10.1016/j.pupt.2010.05.007_bib39 article-title: Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.41.11.2511 contributor: fullname: Occhipinti – volume: 150 start-page: 251 year: 1994 ident: 10.1016/j.pupt.2010.05.007_bib4 article-title: High incidence of silent aspiration in elderly patients with community-acquired pneumonia publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.150.1.8025758 contributor: fullname: Kikuchi – volume: 46 start-page: 2920 year: 2002 ident: 10.1016/j.pupt.2010.05.007_bib15 article-title: Consumption of imipenem correlates with ß-lactam resistance in Pseudomonas aeruginosa publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.46.9.2920-2925.2002 contributor: fullname: Lepper – volume: 42 start-page: 26 issue: S2 year: 1994 ident: 10.1016/j.pupt.2010.05.007_bib41 article-title: Evaluation of antimicrobial effects and optimal ratio of tazobactam/piperacillin combination (in Japanese) publication-title: Chemotherapy contributor: fullname: Higashiya – volume: 336 start-page: 243 year: 1997 ident: 10.1016/j.pupt.2010.05.007_bib17 article-title: A prediction rule to identify low-risk patients with community-acquired pneumonia publication-title: N Engl J Med doi: 10.1056/NEJM199701233360402 contributor: fullname: Fine – volume: 39 start-page: 445 year: 1995 ident: 10.1016/j.pupt.2010.05.007_bib25 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.39.2.445 contributor: fullname: Cometta – volume: 171 start-page: 388 year: 2005 ident: 10.1016/j.pupt.2010.05.007_bib30 article-title: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200405-644ST contributor: fullname: American Thoracic Society; Infectious Diseases Society of America – volume: 26 start-page: 346 year: 1998 ident: 10.1016/j.pupt.2010.05.007_bib35 article-title: Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial publication-title: Clin Infect Dis doi: 10.1086/516294 contributor: fullname: Brun-Buisson – volume: 43 start-page: 389 year: 1999 ident: 10.1016/j.pupt.2010.05.007_bib34 article-title: Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection publication-title: J Antimicrob Chemother doi: 10.1093/jac/43.3.389 contributor: fullname: Joshi – year: 2007 ident: 10.1016/j.pupt.2010.05.007_bib3 contributor: fullname: Ministry of Health Labour and Welfare, Government of Japan – volume: 48 start-page: 129 year: 2009 ident: 10.1016/j.pupt.2010.05.007_bib12 article-title: Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients publication-title: Intern Med doi: 10.2169/internalmedicine.48.1308 contributor: fullname: Tokuyasu – volume: 30 start-page: 2335 year: 2008 ident: 10.1016/j.pupt.2010.05.007_bib40 article-title: Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002 publication-title: Clin Ther doi: 10.1016/j.clinthera.2008.12.009 contributor: fullname: Frei – volume: 344 start-page: 665 year: 2001 ident: 10.1016/j.pupt.2010.05.007_bib21 article-title: Aspiration pneumonitis and aspiration pneumonia publication-title: N Engl J Med doi: 10.1056/NEJM200103013440908 contributor: fullname: Marik – volume: 108 start-page: 937 year: 1995 ident: 10.1016/j.pupt.2010.05.007_bib5 article-title: The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess publication-title: Chest doi: 10.1378/chest.108.4.937 contributor: fullname: Hammond – volume: 56 start-page: 872 year: 2005 ident: 10.1016/j.pupt.2010.05.007_bib24 article-title: Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients publication-title: J Antimicrob Chemother doi: 10.1093/jac/dki348 contributor: fullname: Edmiston – volume: 167 start-page: 1650 year: 2003 ident: 10.1016/j.pupt.2010.05.007_bib8 article-title: Microbiology of severe aspiration pneumonia in institutionalized elderly publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200212-1543OC contributor: fullname: El-Solh – volume: 43 start-page: 1379 year: 1999 ident: 10.1016/j.pupt.2010.05.007_bib14 article-title: Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.43.6.1379 contributor: fullname: Carmeli – volume: 56 start-page: 202 year: 1974 ident: 10.1016/j.pupt.2010.05.007_bib7 article-title: The bacteriology of aspiration pneumonia publication-title: Am J Med doi: 10.1016/0002-9343(74)90598-1 contributor: fullname: Bartlett – year: 2004 ident: 10.1016/j.pupt.2010.05.007_bib2 contributor: fullname: World Health Organization – volume: 42 start-page: 281 issue: S2 year: 1994 ident: 10.1016/j.pupt.2010.05.007_bib36 article-title: Evaluation of emergence of beta-lactam resistance in Pseudomonas aeruginosa (in Japanese) publication-title: Chemotherapy contributor: fullname: Matsumoto – volume: 5 start-page: 569 year: 2002 ident: 10.1016/j.pupt.2010.05.007_bib38 article-title: Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam publication-title: Pharmacotherapy doi: 10.1592/phco.22.8.569.33209 contributor: fullname: Kim – volume: 32 start-page: 269 year: 2008 ident: 10.1016/j.pupt.2010.05.007_bib37 article-title: Strategic use of antimicrobial agents based on pharmacokinetics-pharmacodynamics (PK-PD) theory (in Japanese) publication-title: ICC & CCU contributor: fullname: Mikamo – year: 2007 ident: 10.1016/j.pupt.2010.05.007_bib1 doi: 10.18356/fe74b223-en contributor: fullname: United Nations Population Division – volume: 135 start-page: 633 year: 2009 ident: 10.1016/j.pupt.2010.05.007_bib27 article-title: Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital publication-title: Chest doi: 10.1378/chest.08-1357 contributor: fullname: Shindo – volume: 41 start-page: 345 year: 2005 ident: 10.1016/j.pupt.2010.05.007_bib10 article-title: Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction publication-title: Clin Infect Dis doi: 10.1086/431588 contributor: fullname: Templeton – volume: 127 start-page: 1276 year: 2005 ident: 10.1016/j.pupt.2010.05.007_bib11 article-title: Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients publication-title: Chest doi: 10.1378/chest.127.4.1276 contributor: fullname: Kadowaki – ident: 10.1016/j.pupt.2010.05.007_bib18 – volume: 51 start-page: 3568 year: 2007 ident: 10.1016/j.pupt.2010.05.007_bib28 article-title: Health care-associated pneumonia and community-acquired pneumonia: a single-center experience publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00851-07 contributor: fullname: Micek – volume: 36 start-page: 23 year: 2008 ident: 10.1016/j.pupt.2010.05.007_bib19 article-title: German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess publication-title: Infection doi: 10.1007/s15010-007-7043-6 contributor: fullname: Ott – volume: 45 start-page: 995 year: 2006 ident: 10.1016/j.pupt.2010.05.007_bib13 article-title: Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia publication-title: Intern Med doi: 10.2169/internalmedicine.45.1717 contributor: fullname: Yanagihara – volume: 128 start-page: 3854 year: 2005 ident: 10.1016/j.pupt.2010.05.007_bib29 article-title: Epidemiology and outcomes of health-care-associated pneumonia. Results from a large US database of culture-positive pneumonia publication-title: Chest doi: 10.1378/chest.128.6.3854 contributor: fullname: Kollef – volume: 34 start-page: 127 year: 2006 ident: 10.1016/j.pupt.2010.05.007_bib33 article-title: Piperacillin/tazobactam vs imipenem/vilastatin in the treatment of nosocomial pneumonia—a double blind prospective multicentre study publication-title: Infection doi: 10.1007/s15010-006-5020-0 contributor: fullname: Schmitt – volume: 100 start-page: 1554 year: 2006 ident: 10.1016/j.pupt.2010.05.007_bib32 article-title: Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia publication-title: Respir Med doi: 10.1016/j.rmed.2006.01.004 contributor: fullname: Joshi |
| SSID | ssj0007435 |
| Score | 2.0967078 |
| Snippet | Abstract Background Treatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of... Treatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin (TAZ/PIPC) in... BACKGROUNDTreatment of aspiration pneumonia is becoming an important issue due to aging of populations worldwide. Effectiveness of tazobactam/piperacillin... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 403 |
| SubjectTerms | Aged, 80 and over Anti-Bacterial Agents - therapeutic use Aspiration Cilastatin - therapeutic use Community-Acquired Infections - drug therapy Community-Acquired Infections - microbiology Community-acquired pneumonia (CAP) Drug Combinations Female Humans Imipenem - therapeutic use Imipenem/cilastain (IPM/CS) Injections, Intravenous Male Medical Education Nursing home-acquired pneumonia (NHAP) Nursing Homes Open-label randomized study Penicillanic Acid - analogs & derivatives Penicillanic Acid - therapeutic use Piperacillin - therapeutic use Pneumonia, Aspiration - drug therapy Pneumonia, Aspiration - microbiology Prospective Studies Protease Inhibitors - therapeutic use Pulmonary/Respiratory Tazobactam/piperacillin (TAZ/PIPC) Treatment Outcome |
| Title | Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: Comparison with imipenem/cilastatin |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1094553910000726 https://dx.doi.org/10.1016/j.pupt.2010.05.007 https://www.ncbi.nlm.nih.gov/pubmed/20561917 https://search.proquest.com/docview/748967691 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CCqWX0qav7SPoUHJp1PVDjqXewtKwfSQs7QZyE7IsgwPrNbH3kB566C_vjCzvUkp66MlgJI-lGc1D-mYE8FaIylljY57YqOSUqsnlick4XXSblsLK1BfSPr84mV-Kz1fZ1R7MxlwYglUG3T_odK-tw5tpmM1pW9fT7zFGJlmWKr9DnSdUdlug-UOZfv9zB_NAC5n5E08lOLUOiTMDxqvdtH2Ad9HWSn6XcbrL-fRG6OwRPAzeIzsdfvAx7LnmAO6fh_PxAzhaDJWob4_ZcpdY1R2zI7bY1ai-fQK_luYHrmTbmxUOs8WmljZeGoY-LKPbcaiCBO_XHP_N3TjWNm6DAlsbhm1CLdaO0SYuI3C672aGQ3tk9Ac2215vODSqV0ikcaspkjGUxFQ3T-Hy7ONyNufhOgZuhZI9L1JhKpk7GYnCGFXFrkTLVuGaR21bYWSUyEKRuU-NjSTOe2FkpaQi3E0pVJQ-g_1m3bgXwGSJMTnGJkWeWhFLhV8rURMkeaQkyoyYwLuRD7odqm7oEY52rYlrmrimo0wj1yaQj6zSYz4pakDXheXY6Vh3iY70XyIzgWzb8w-p02hQ_kmRjRKhcTnSGYtp3HrTaSrmQ6jheALPB0nZDiChYA2j45f_SfQVPPDQBY8kfA37_c3GvUGPqC8Ovcgfwr3T2bevC3p--jK_-A04eg0V |
| link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIkEvCMqjy9MH1As1m4ezsblVK6oFulUltlJvlpM4UpA2GzXZQ3vogV_OjOPsClXlwDWy48eM5-VvxgAfhShtbvKQR3lQcErV5HJiEk4P3caFyGXsCmnPzyazC_H9MrncgemQC0OwSi_7e5nupLX_Mva7OW6qavwzRM8kSWLlItRpNHkADwXZx8jUn2-3OA9UkYm78lSCU3OfOdODvJp103l8F8VW0vu0033Wp9NCJ0_hiTcf2XE_w2ewY-t9eDT3F-T7cHjel6K-PmKLbWZVe8QO2fm2SPX1c_i9MDd4lPPOLHGdDTbNKfJSMzRiGT2PQyUkeLfiODd7ZVlT2zVybGUYtvHFWFtGUVxG6HTXzfS39kjpL2y6ed-wb1QtcZDaLsc4jKEspqp-ARcnXxfTGffvMfBcKNnxLBamlKmVgciMUWVoC1RtJR56FLclukaRzBTp-9jkgcR9z4wslVQEvCmECuKXsFuvansATBbolKNzkqVxLkKp8G8FioIoDZREphEj-DTQQTd92Q094NF-aaKaJqrpINFItRGkA6n0kFCKItC2_jy2OtRtpAN9h2dGkGx6_sV2GjXKP0dkA0doPI90yWJqu1q3mqr5EGw4HMGrnlM2C4jIW0P3-PV_DvoBHs8W81N9-u3sxxvYczgGByt8C7vd1dq-Q_Ooy9479v8D9vQNGQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tazobactam%2Fpiperacillin+for+moderate-to-severe+pneumonia+in+patients+with+risk+for+aspiration%3A+comparison+with+imipenem%2Fcilastatin&rft.jtitle=Pulmonary+pharmacology+%26+therapeutics&rft.au=Ito%2C+Isao&rft.au=Kadowaki%2C+Seizo&rft.au=Tanabe%2C+Naoya&rft.au=Haruna%2C+Akane&rft.date=2010-10-01&rft.eissn=1522-9629&rft.volume=23&rft.issue=5&rft.spage=403&rft_id=info:doi/10.1016%2Fj.pupt.2010.05.007&rft_id=info%3Apmid%2F20561917&rft.externalDocID=20561917 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10945539%2FS1094553910X00050%2Fcov150h.gif |